Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial

Anaplastic lymphoma kinase (ALK) inhibition is expected to be a promising therapeutic strategy for ALK‐positive malignancies. We aimed to examine the efficacy and safety of alectinib, a second‐generation ALK inhibitor, in patients with relapsed or refractory ALK‐positive anaplastic large cell lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukano, Reiji, Mori, Tetsuya, Sekimizu, Masahiro, Choi, Ilseung, Kada, Akiko, Saito, Akiko Moriya, Asada, Ryuta, Takeuchi, Kengo, Terauchi, Takashi, Tateishi, Ukihide, Horibe, Keizo, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734006/
https://www.ncbi.nlm.nih.gov/pubmed/33010107
http://dx.doi.org/10.1111/cas.14671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734006/
https://www.ncbi.nlm.nih.gov/pubmed/33010107
http://dx.doi.org/10.1111/cas.14671

Ejemplares similares